Developed at the University of Michigan by Leroy Townsend, Ph.D., Chimerix’s library of chemical leads consists of a broad range of 10,000+ nucleoside and heterocyclic compounds focused on key antiviral and oncology targets. The majority of Dr. Townsend’s research efforts focused on antimetabolites, an approach that has been successfully employed in the search for potent antiviral, antibacterial, anti-parasitic and anti-cancer agents.
Chimerix has identified multiple novel classes of compounds and several nucleoside analogs with potent activity against hepatitis C virus (HCV), which have the potential to address a market in excess of $4 billion worldwide. We plan to select a lead candidate for preclinical development as well as additional promising back-up compounds.
The library is also being screened for compounds with activity against influenza A and B, dengue virus, malaria and tuberculosis.